Lantern Pharma Inc. (LTRN) Investor Relations Documents

Lantern Pharma Inc. (LTRN) investor relations documents from the company's IR site: 9 presentations, 31 press releases; latest deck 2026-07-13. Read in-app with summaries. First-party data.

Download PDF file, (opens in new window): Lantern Pharma (NASDAQ: LTRN) uses its RADR AI platform to accelerate oncology drug development, claiming 70% faster timelines and 80% lower costs.

Investor relations documents — source: company IR site
PublishedTypeDocument
2026-08-14Press releaseLantern Pharma Reports Second Quarter 2026 Financial Results and Provides Business Update
2026-08-07Press releaseLantern Pharma to Report Second Quarter 2026 Operating & Financial Results on August 14th, 2026 at 9:00 a.m. ET
2026-08-03Press releaseLantern Pharma (Nasdaq: LTRN) Establishes Open-Medicine AI as a Separate Company to Commercialize and Expand Its Multi-A
2026-07-28Press releaseLantern Pharma to Advance EMA-Cleared Phase 1b/2 Trial of LP-184 (Zirdafulven) in Biomarker-Selected Advanced Bladder Ca
2026-07-13PresentationDownload PDF file, (opens in new window)
2026-06-02Press releaseDownload , Lantern Pharma Reports HARMONIC™ Data Showing LP-300 Progression-Free Survival Benefit Deepens with Treatment
2026-05-19Press releaseDownload , Lantern Pharma Announces Successful Outcome of FDA Type C Meeting Request for HARMONIC™ Phase 2 Trial of LP-3
2026-05-19Press releaseLantern Pharma Announces Successful Outcome of FDA Type C Meeting Request for HARMONIC™ Phase 2 Trial of LP-300 in Never
2026-05-15Press releaseLantern Pharma to Report First Quarter 2026 Operating & Financial Results on May 15th, 2026
2026-05-15Press releaseEarnings Release of Q1 2026, PDF file, (opens in new window)
2026-05-11Press releaseDownload , Lantern Pharma to Report First Quarter 2026 Operating & Financial Results on May 15th, 2026, May 11, 2026, (o
2026-05-01PresentationDownload PDF (opens in new window)
2026-04-09Press releaseLantern Pharma Invites Investors, Analysts & Shareholders to Experience the Future of Drug Discovery via a Live Demo of
2026-04-02Press releaseDownload , Lantern Pharma Invites Investors, Analysts & Shareholders to Experience the Future of Drug Discovery via a Li
2026-03-30Earnings deckPresentation Open Event Link, PDF file, March 30, 2026, (opens in new window)
2026-03-30Press releaseLantern Pharma to Report Fourth Quarter and Fiscal Year 2025 Operating & Financial Results on March 30th, 2026 at 4:30 p
2026-03-30Press releaseDownload , Lantern Pharma Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates, Mar
2026-03-30Press releaseEarnings Release of Q4 2025 Press Release, (opens in new window)
2026-03-27Press releaseDownload , Lantern Pharma Confirms Panna Sharma Continues to Serve as President and CEO; Alerts Investors to False Third
2026-03-23Press releaseDownload , Lantern Pharma to Report Fourth Quarter and Fiscal Year 2025 Operating & Financial Results on March 30th, 202
2026-02-17Press releaseLantern Pharma to Present at the 7th Glioblastoma Drug Development Summit in Boston on February 17-19, 2026
2026-02-10Press releaseDownload , Lantern Pharma to Present at the 7th Glioblastoma Drug Development Summit in Boston on February 17-19, 2026,
2026-01-20Press releaseDownload , Lantern Pharma's LP-284 Receives FDA Orphan Drug Designation for Soft Tissue Sarcomas, January 20, 2026, (ope
2025-03-27Press releaseEarnings Release
2025-03-27Press releaseQ4
2025-03-27Earnings deckQ4
2024-11-07Press releaseEarnings Release
2024-11-07Earnings deckQ3
2024-11-07Press releaseQ3
2024-08-08Earnings deckQ2
2024-08-08Press releaseQ2
2024-05-09Press releaseEarnings Release
2024-05-09Press releaseEarnings Release
2024-05-09PresentationQ1
2024-03-18Press releaseEarnings Release
2024-03-18Press releaseEarnings Release
2024-03-18Earnings deckQ4
2023-11-08Press releaseEarnings Release
2023-11-08PresentationQ3
2023-08-09Press releaseEarnings Release

LTRN overview · LTRN earnings · LTRN financials · LTRN KPIs · LTRN ownership · LTRN peers · LTRN filings

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.